D. Nemazee

Structural and mechanistic insights into disease-associated endolysosomal exonucleases PLD3 and PLD4

This study reports the structures and mechanistic insights of PLD3 and PLD4, revealing their exonuclease activity, phosphatase function, and disease relevance.

Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift

The paper identifies broadly neutralizing antibodies against SARS-CoV-2 that target conserved regions on the spike RBD, showing resistance to antigenic drift and suggesting potential vaccine targets.

Efficient isolation of rare B cells using next-generation antigen barcoding

This paper introduces a method for efficiently isolating rare antigen-specific B cells using next-generation antigen barcoding and a computational framework, demonstrating its ability to recover thousands of mAbs, including rare HIV broadly neutralizing antibodies.

Broadly neutralizing antibodies target the coronavirus fusion peptide

The paper identifies six monoclonal antibodies that broadly neutralize coronaviruses by targeting the conserved fusion peptide.

A broad and potent neutralization epitope in SARS-related coronaviruses

The paper identifies a broadly neutralizing epitope in SARS-related coronaviruses that is effective against variants, including Omicron, and suggests its use for universal vaccine design.

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease

The paper identifies broadly neutralizing antibodies targeting the S2 region of betacoronavirus spikes that protect against SARS-CoV-1, SARS-CoV-2, and MERS-CoV.

Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape

This study engineers SARS-CoV-2 neutralizing antibodies through directed evolution to enhance their potency and reduce viral escape.

Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques

This study shows that rhesus macaques can be immunized to produce broadly neutralizing antibodies against multiple SARS-related viruses, highlighting differences in B cell repertoires between humans and macaques.

Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution

This paper describes engineering a SARS-CoV-1 neutralizing antibody to effectively neutralize SARS-CoV-2 through directed evolution and affinity maturation.

In vivo engineered B cells retain memory and secrete high titers of anti-HIV antibodies in mice

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants

This study identifies ultrapotent bispecific antibodies that neutralize emerging SARS-CoV-2 variants by targeting multiple spike protein regions, showing efficacy in vitro and in a hamster model.

A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection

This study identifies a broadly neutralizing antibody that targets a conserved site on beta-coronavirus spike proteins and provides protection against SARS-CoV-2 infection.

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

The paper examines how mutations at E484 and K417 in SARS-CoV-2 variants affect neutralizing antibodies, showing reduced efficacy against certain antibody families but not others.

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

This study shows that combining cross-neutralizing antibodies CV38-142 and COVA1-16 enhances neutralization of SARS-CoV-2 and SARS-CoV pseudoviruses.

An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19

This study engineers an antibody, ADG-2, that broadly neutralizes SARS-CoV and SARS-CoV-2 in mice, offering protection against respiratory disease and viral replication.

Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

The paper examines cross-reactive serum and memory B cell responses to SARS-CoV-2 and endemic coronaviruses, finding weak serum cross-reactivity but stronger memory B cell cross-reactivity.

A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody

This study identifies a single amino acid mutation that determines the difference in neutralization ability of a cross-reactive antibody between SARS-CoV-2 and SARS-CoV.

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

The paper uses cryo-EM and glycan analysis to study the structure of a full-length SARS-CoV-2 spike protein in a vaccine candidate, revealing its stable prefusion conformation and novel trimer interactions.

Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein

The paper identifies broadly neutralizing antibodies against SARS-CoV-2 and related sarbecoviruses, highlighting a conserved epitope on the spike protein as a potential vaccine target.

Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model

This study rapidly identifies potent SARS-CoV-2 neutralizing antibodies and demonstrates their protective efficacy in an animal model.

Vaccine Elicitation of HIV Broadly Neutralizing Antibodies from Engineered B cells

This study shows that engineered HIV bnAb-expressing B cells can be expanded in vivo after vaccination, leading to durable bnAb memory and long-lived plasma cells.

B cells expressing authentic naive human VRC01-class BCRs can be primed and recruited to germinal centers in multiple independent mouse models

The paper demonstrates that authentic naive human VRC01-class BCRs can be primed and recruited to germinal centers in multiple mouse models, validating germline-targeting vaccine design.

Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens

The paper evaluates de novo-designed two-component nanoparticles for presenting HIV Env trimers, showing improved antibody responses through multivalent display.

Reprogramming the antigen specificity of B cells using genome-editing technologies

This study reprograms B cells to express HIV-specific BCRs by editing immunoglobulin genes with CRISPR-Cas9, enabling improved anti-HIV neutralizing activity.

HIV-1 vaccine design through minimizing envelope metastability

This paper demonstrates that gp41ECTO is the main source of HIV-1 envelope metastability and shows that stabilizing it improves nanoparticle assembly and induces more effective tier 2 neutralizing antibodies.